SARS-CoV-2 variants of concern as of June 9, 2022

  • UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 35: UKHSA; 2022[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf

  • Hui KPY, Ho JCW, Cheung Mc, Ng Kc, Ching RHH, Lai Kl et al. Replication of the SARS-CoV-2 Omicron variant in human bronchi and lung ex vivo. temper nature. 2022; 603 (7902): 715-20.

  • UK Health Security Agency. COVID-19 Vaccine Surveillance Report Week 6 2022[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6PDF[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6pdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6بيديإف[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6pdf

  • Rössler A, Knabl L, Laer Dv, Kimpel J. Neutralization profile of diverse convalescent individuals in Omicron. medRxiv. 2022: 2022.02.01.22270263.

  • Al-Tarawneh H, Schmitli H, Hassan Murr, Ayoub H, Qassem S, Miqdad, et al. Protection against the Omicron variant of previous SARS-CoV-2 infection. In Engel J Med. 2022.

  • European Center for Disease Prevention and Control. Assessment of the additional prevalence and potential impact of the omicron variant SARS-CoV-2 of concern in the EU/EEA, 19th update 2022[availablefrom:https://wwwecdceuropaeu/sites/default/files/documentation/RRA-19-update-27-jan-2022pdf[Availablefrom:https://wwwecdceuropaeu/sites/default/files/documents/RRA-19-update-27-jan-2022pdf[متاحمن:https://wwwecdceuropaeu/sites/default/files/الوثائق/RRA-19-update-27-jan-2022pdf[Availablefrom:https://wwwecdceuropaeu/sites/default/files/documents/RRA-19-update-27-jan-2022pdf

  • Faria NR, Mellan TA, Whittaker C, Clear IM, Candido DdS, Mishra S et al. Genomics and epidemiology of the P.1 SARS-CoV-2 strain in Manaus, Brazil. Sciences. 2021.

  • UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing: Update on Hospitalization and Vaccine Efficacy for Omicron VOC-21NOV01 (B.1.1.529) UKHSA; 2021[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf

  • Lyngse FP, Kirkeby CT, Denwood M, Christianen LE, Mølbak K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron VOC sub variants BA.1 and BA.2: evidence from Danish families. medRxiv. 2022: 2022.01.28.22270044.

  • Fonager J, Bennedbæk M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular epidemiology of the substrain of the SARS-CoV-2 variant Omicron BA.2 in Denmark, November 29, 2021 to January 2, 2022. Eurosurveillance. 2022; 27 (10): 2

  • UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England – Technical Briefing 39: UKHSA; 2022[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf

  • Khan K, Karim F, Ganga Y, Bernstein M, Jules Z, Redoy K, et al. Omicron substrains BA.4/BA.5 escaping BA.1 elicited neutralizing immunity. medRxiv. 2022: 2022.04.29.22274477.

  • Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L et al. Antibodies caused by omicron infection BA.2.12.1, BA.4 and BA.5. bioRxiv. 2022: 2022.04.30.489997.

  • Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and effect of the SARS-CoV-2 B.1.1.7 strain in England. Sciences. 2021; 372.

  • Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S et al. Increased mortality in community-tested cases of SARS-CoV-2 B.1.1.7. temper nature. 2021.

  • Funk T, Pharris A, Spiteri G, Bundle N, Melido A, Carr M et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. European monitoring. 2021; 26 (16): 2100348.

  • Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Alshammary H, Amoako AA, et al. The SARS-CoV-2 spike E484K mutation reduces the neutralization of the antibody. Lancet microbe.

  • Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine antibodies. temper nature. 2021.

  • Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK et al. Transmission and inactivation of an antibody to an emerging variant of SARS-CoV-2 in California carrying the L452R protein mutation. medRxiv. 2021.

  • French public health. New variant discovered and under surveillance in Brittany 2021[updatedon16-03-2021Availablefrom:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detect-et-sous-surveillance-en-bretagne[updated2021-03-16Availablefrom:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detecte-et-sous-surveillance-en-bretagne[تمالتحديثفي2021-03-16متاحمن:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detect-et-sous-surveillance-en-bretagne[updated2021-03-16Availablefrom:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detecte-et-sous-surveillance-en-bretagne

  • Shu Y, McCauley J. GISAID: A global initiative to share all influenza data–from vision to reality. European monitoring. 2017; 22 (13): 30494.

  • Zhao X, Zheng A, Li D, Zhang R, Sun H, Wang Q et al. Anti-ZF2001 neutralization of SARS-CoV-2 variants. Lancet microbe. 2021.

  • England PH. SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 11 2021[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf[Availablefrom:https://assetspublishingserviceloadsgov/uploads/system/uptach_98]/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf

  • Tut G, Lancaster T, Krutikov M, Sylla P, Bone D, Kaur N et al. Profile of humoral and cellular immune responses to a single BNT162b2 or ChAdOx1 vaccine in residents and staff within residential care homes (VIVALDI Study). Preprints with The Lancet 2021.

  • Tada T, Chu H, Dacosta BM, Samanovic ME, Mulligan MG, Landau NR. The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India confer partial resistance to vaccine-generated therapeutic monoclonal antibodies. bioRxiv. 2021.

  • Hoffmann M, Hoffmann-Winckler H, Krueger N, Kempf A, Nihlmayer I, Gration L, et al. The B.1.617 SARS-CoV-2 variant is resistant to Bamlanivimab and avoids antibodies caused by infection and vaccination. bioRxiv. 2021.

  • Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY et al. Neutralization of the variant under consideration B.1.617 with BBV152 vaccine serum. bioRxiv. 2021.

  • Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, et al. Identification of SARS-CoV-2 mutations that attenuate neutralization of monoclonal antibodies and serum. Host cell and microbe. 2021; 29 (3): 477-88.e4.

  • Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. The detection of SARS-CoV-2 is of concern in South Africa. temper nature. 2021; 592 (7854): 438-43.

  • Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G et al. SARS-CoV-2 501Y.V2 escape from neutralization by convalescent plasma. temper nature. 2021.

  • Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine. 2021.

  • Pearson California. Estimates of severity and transmission of the novel SARS-CoV-2 variant in South Africa 501Y.V2[Availablefrom:https://cmmidgithubio/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf[Availablefrom:https://covid/covid19]/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf[متاحمن:https://cmmidgithubio/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf[Availablefrom:https://cmmidgithubio/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf

  • Greeny AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor binding domain that affect the recognition of polyclonal human plasma antibodies. Host cell and microbe. 2021; 29 (3): 463-76.e6.

  • Haynes WA, Kamath K, Lucas C, Shon J, Iwasaki A. Effect of B.1.1.7 variant mutations on SARS-CoV-2 linear epitope antibody recognition. medRxiv. 2021: 2021.01.06.20248960.

  • Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, et al. Furin cleavage site is key to SARS-CoV-2 pathogenesis. bioRxiv. 2020.

  • Acevedo ML, Alonso-Palomares L, Bustamante A, Gaggero A, Paredes F, Cortés CP, et al. Infection and immune escape of a novel SARS-CoV-2 variant from Lambda. medRxiv. 2021.

  • Tada T, Chu H, Dacosta BM, Samanovic ME, Mulligan MG, Landau NR. The SARS-CoV-2 Lambda variant remains susceptible to neutralization by antibodies extracted from vaccine mRNA and convalescent serum. bioRxiv. 2021.

  • UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants Under Investigation in England (Technical Briefing 27) 2021[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/Technical-briefing-27pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/technical-briefing-27pdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/Technical-briefing-27pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/technical-briefing-27pdf

  • Lassauniere R, Polacek C, Fonager J, Bennedbaek M, Boding L, Rasmussen M et al. Neutralization of the SARS-CoV-2 Delta substrain AY.4.2 and B.1.617.2 + E484K by sera from BNT162b2 mRNA vaccine. medRxiv. 2021: 2021.11.08.21266075.

  • Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM et al. The antibody is evaded by the P.1 strain of SARS-CoV-2. cell. 2021

  • Public Health England. SARS-CoV-2 Variants of Concern and Variables Under Investigation in England Technical Brief 12 2021[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf[Availukpublishing:https://assetspublishfrom:government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf[متوفرمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf

  • Jimmy Lopez Bernal NA, Charlotte Gower, Ellen Gallagher, Dr. Zambon, Kevin Brown, Susan Hopkins, Mira Chand, Mary Ramsay. Efficacy of COVID-19 vaccines against B.1.617.2 2021 variant[Availablefrom:https://khubnet/documents/135939561/42+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42[Availablefrom:https://khubnet/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+the+B16172+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42[متاحمن:https://khubnet/documents/135939561/42+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42[Availablefrom:https://khubnet/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+the+B16172+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42

  • Sheikh A, McMenamin C, Taylor B, Robertson C. SARS-CoV-2 delta VOCs in Scotland: demographics, risk of hospitalization, and vaccine efficacy. scalpel;

  • Stowe J, Andrews N, Gower C, Gallagher E, Otsy L, Simmons R, et al. Efficacy of COVID-19 vaccines against hospitalization with delta variant (B.1.617.2) 2021[availablefrom:https://khubnet/documents/135939561/479607266/Effectivity+of+COVID-19+vaccines+against+hospital+with+delta+%28B16172%29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431[Availablefrom:https://khubnet/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against++admission+with+the+Delta+%28B16172%29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431[متوفرمن:https://khubnet/documents/135939561/479607266/Effectivity+of+COVID-19+vaccines+against+دخولالمستشفى+مع+دلتا+٪28B16172٪29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997؟t=1623689315431[Availablefrom:https://khubnet/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B16172%29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431

  • Public Health England. SARS-CoV-2 Variants of Concern and Variables Under Investigation in England Technical Brief 16 2021[availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf[Availablepublishfrom:https://servicespublishing:https://servicespublishinggovernment/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf[متوفرمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf

  • Leave a Reply

    Your email address will not be published.